Review
Adverse events associated with immune checkpoint inhibitor treatment for cancer
Khashayar Esfahani, Nicholas Meti, Wilson H. Miller and Marie Hudson
CMAJ January 14, 2019 191 (2) E40-E46; DOI: https://doi.org/10.1503/cmaj.180870
Khashayar Esfahani
Department of Medicine (Esfahani, Meti, Miller, Hudson), McGill University; Departments of Medicine and Oncology (Esfahani, Miller), McGill University and Jewish General Hospital, Rossy Cancer Network; Division of Rheumatology and Lady Davis Institute (Hudson), Jewish General Hospital, Montreal, Que.
MDNicholas Meti
Department of Medicine (Esfahani, Meti, Miller, Hudson), McGill University; Departments of Medicine and Oncology (Esfahani, Miller), McGill University and Jewish General Hospital, Rossy Cancer Network; Division of Rheumatology and Lady Davis Institute (Hudson), Jewish General Hospital, Montreal, Que.
MDWilson H. Miller Jr.
Department of Medicine (Esfahani, Meti, Miller, Hudson), McGill University; Departments of Medicine and Oncology (Esfahani, Miller), McGill University and Jewish General Hospital, Rossy Cancer Network; Division of Rheumatology and Lady Davis Institute (Hudson), Jewish General Hospital, Montreal, Que.
MD PhDMarie Hudson
Department of Medicine (Esfahani, Meti, Miller, Hudson), McGill University; Departments of Medicine and Oncology (Esfahani, Miller), McGill University and Jewish General Hospital, Rossy Cancer Network; Division of Rheumatology and Lady Davis Institute (Hudson), Jewish General Hospital, Montreal, Que.
MD MPHData supplements
Earn CPD Credits
This article is eligible for 0.5 Mainpro+ credits.
Did you read this article?
Note: The YES link above may not work in certain versions of Internet Explorer 8. If you are having difficulties with this link, please try another browser.
Related Articles
In this issue
Article tools
Respond to this article
Adverse events associated with immune checkpoint inhibitor treatment for cancer
Khashayar Esfahani, Nicholas Meti, Wilson H. Miller, Marie Hudson
CMAJ Jan 2019, 191 (2) E40-E46; DOI: 10.1503/cmaj.180870
Jump to section
- Article
- What are immune checkpoint inhibitors and how do they work?
- Why do immune-related adverse events occur?
- How are immune-related adverse events diagnosed and managed?
- What is the impact of immune-related adverse events on cancer outcomes?
- Are immune checkpoint inhibitors suitable for patients with pre-existing autoimmune diseases?
- Can we predict which patients will develop immune-related adverse events?
- Conclusion
- Footnotes
- References
- Figures & Tables
- Related Content
- Responses
- Metrics
Related Articles
Cited By...
- Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer
- Recommendations for standardizing biopsy acquisition and histological assessment of immune checkpoint inhibitor-associated colitis
- Immunotherapy
- Limmunotherapie
- The MNK1/2-eIF4E axis drives melanoma plasticity, progression, and resistance to immunotherapy
- Enteritis with immune checkpoint inhibitor use